Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410948 | 0.86 | CYP4F2 (0.57) | MAOBCYP4F2CYP4A11CYP11B1MAOA | |
| SCHEMBL5409358 | 0.82 | MAOB (0.61) | MAOBCDC7ROCK2RAB9AMEN1 | |
| SCHEMBL2570284 | 0.82 | CDC7 (0.61) | MAOBCYP3A4CDC7ROCK2RAB9A | |
| SCHEMBL5415318 | 0.81 | MAOB (0.59) | MAOBCYP11B1MAOACDC7ROCK2 | |
| SCHEMBL5412496 | 0.77 | TRPA1 (0.54) | MAOBCDC7KCNH2ROCK2 | |
| SCHEMBL774832 | 0.76 | TRPA1 (0.54) | MAOBMAOAROCK2RAB9AMEN1 | |
| SCHEMBL29740998 | 0.76 | TRPA1 (0.54) | MAOBMAOAROCK2RAB9AMEN1 | |
| SCHEMBL29741480 | 0.76 | MAOB (0.81) | MAOBCYP4F2CYP4A11CYP3A4MAOA | |
| SCHEMBL18664184 | 0.76 | MAOB (0.81) | MAOBCYP4F2CYP4A11CYP3A4MAOA | |
| SCHEMBL29941810 | 0.76 | MAOB (0.70) | MAOBCYP3A4MAOASCN7AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAOB 2025/4885CYP4F2 3069/4885CYP4A11 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.